Director, New Product Planning

Does it excite you to shape enterprise-wide commercial strategy for pipeline assets, and do you have experience with New Product Planning across early development through Phase 3 readiness? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.

Your new position
As Director, New Product Planning (NPP), you will bridge science and commercial strategy to help shape the future of our pipeline. Working closely with R&D, Commercial and Business Development (BD), you will translate market, competitive and clinical insights into actionable asset plans that maximize long-term value creation. This is an opportunity to influence high-impact decisions and help ensure pipeline assets are commercially compelling from early development through Phase 3 readiness.

We offer exciting responsibilities:

• Lead commercial strategy for pipeline assets from early development through proof of concept and Phase 3 readiness
• Integrate market, competitive and clinical insights into asset strategies and target product profiles (TPPs) to guide development choices
• Represent Commercial in cross-functional project teams, ensuring commercial input informs key development milestones
• Contribute to portfolio trade-off discussions and investment recommendations with evidence-based insights and strategic options
• Drive lifecycle planning and support market readiness activities for pipeline assets
• Support BD with commercial evaluations of external opportunities, as needed

Your profile
This role suits a strategic, collaborative leader who can translate complex scientific and market inputs into clear choices and recommendations. Success requires strong cross-functional influence, structured thinking, and the ability to build alignment while constructively challenging assumptions.

• Extensive experience in pharma/biotech across commercial and R&D-facing roles
• Proven expertise in New Product Planning, Commercial Strategy, and asset positioning
• Strong understanding of the drug development process and value drivers across stages
• Demonstrated leadership and ability to influence across senior, cross-functional stakeholders
• Ability to develop and communicate TPPs and scenario-based recommendations for governance and portfolio decision-making
• Advanced degree in Life Sciences, Business, or related discipline (MBA or PhD a plus)

Your new team
You will join the Strategy team and work in close partnership with R&D, Commercial and BD, as well as cross-functional project teams, to drive commercial and scientific alignment across pipeline programs.

Let's bond and be bold
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture.

Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold.

Interested in bonding with us? Then please apply no later than March 5, 2026, or as soon as possible. The applications will be reviewed as they come in. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying.

For further information, please contact Marissa Nicole Ray; Mnr@zealandpharma.com.

We are committed to an inclusive recruitment process and welcome applications from all job applicants.

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.